Navigation Links
Karolinska Development to Divest Portfolio Company
Date:6/29/2010

STOCKHOLM, June 29, 2010 /PRNewswire/ -- Today, Karolinska Development has divested Cogmed, one of Karolinska Development's portfolio companies, to Pearson where it will become part of Pearson's Clinical Assessment business. Karolinska Development and other owners will receive an up front payment, as well as tiered royalties up to double digit levels until June 2012 on Cogmed sales. Karolinska Development holds 51.83 percent of Cogmed. Pearson will take possession on June 29, 2010.

The financial details of the acquisition have not been disclosed.

Redwood Capital Group acted as exclusive financial advisor to Cogmed in connection with the transaction.

TO THE EDITORS

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

About Cogmed

Cogmed was founded in 2001. The company provides scientifically developed and clinically validated software based working memory training products for people with attention deficits. Further, Cogmed supports Swedish and international research within working memory training.http://www.cogmed.com

About Pearson Clinical Assessment

http://www.pearsonassessments.com

About Redwood Capital

Redwood Capital Group is an investment banking firm serving the technology, communications and media & business services industries. The firm focuses on mergers & acquisitions, debt and equity financings, and financial advisory services for its clients worldwide. http://www.redcapgroup.com

    For further information, please contact:

    Conny Bogentoft, CEO Karolinska Development
    Tel: +46(0)706-88-61-43,
    e-mail: conny.bogentoft@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy
2. Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
3. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
4. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
5. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. Marcadia and Lilly Sign Development, License Agreement for Novel Glucagon Program in Severe Hypoglycemia
8. Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline
9. Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering
10. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
11. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
Breaking Medicine News(10 mins):